<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557219</url>
  </required_header>
  <id_info>
    <org_study_id>AMG-NKEBN/225/2007</org_study_id>
    <nct_id>NCT00557219</nct_id>
  </id_info>
  <brief_title>Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery</brief_title>
  <official_title>Influence of Fenoldopam and Ketanserin on Function and Kidney Injury Parameters in Patients With Increased Risk of Acute Kidney Failure After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effect of fenoldopam and ketanserin on kidney
      function preservation in patients at high risk for renal failure after cardiac surgery.
      Acute, oliguric renal failure develops in up to 2% of patients undergoing cardiac surgery.
      Some of them require renal replacement therapy and despite that mortality in this group
      exceeds 30-60%. The investigators await that the use of fenoldopam and/or ketanserin may
      decrease the rate of severe renal failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Informed, signed consent will be obtained from the patient before surgery. In patients with
      acute consciousness disorders, the consent will be obtained from a legal representative and
      confirmed by the local court - accordingly to Polish legacy.

      Patients willing to participate into the study and fulfilling at least one of two inclusion
      criteria will be randomly assigned to one of the three study groups. The treatment will be
      applied for 24 hours.

      Intention to treat analysis will include comparison for differences of continuous,
      homogeneous distributed data with use of parametric tests, parametric or inhomogeneous
      distributed data - with use of nonparametric tests. The treatment effect will be assessed by
      comparison of the odds ratios for primary and secondary outcomes between the groups.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Main cooperator finished cooperation
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cystatin C and NGAL in serum</measure>
    <time_frame>after 24 and 48 hours from treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>β2microglobulin in urine</measure>
    <time_frame>after 24, 48 and 72 hours of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine increase in serum</measure>
    <time_frame>after 24, 48 and 72 hours of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of renal replacement therapy</measure>
    <time_frame>7 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Renal Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group receiving placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving ketanserin infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenoldopam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving fenoldopam infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenoldopam (Corlopam)</intervention_name>
    <description>continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours</description>
    <arm_group_label>Fenoldopam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketanserin (Sufrexal)</intervention_name>
    <description>continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours</description>
    <arm_group_label>Ketanserin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cardiac surgery

          -  at least one risk factor for acute renal failure:

               1. oliguria &lt; 0.5 ml/kg/hour for over 3 hours despite adequate blood volume and
                  furosemide intravenously

               2. at least 60 mg furosemide/12 hours iv to maintain diuresis &gt; 1 ml/kg/hour

        Exclusion Criteria:

          -  refused or none consent

          -  chronic renal failure with chronic renal replacement therapy

          -  chronic increase of serum creatinine &gt; 2 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarzyna Klajbor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiac Anesthesiology, Medical University of Gdańsk</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Romuald Lango, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Cardiac Anesthesiology, Medical University of Gdańsk</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiac Anesthesiology, Medical University of Gdańsk</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.informator.gumed.edu.pl/327</url>
    <description>home page of the Dept. of Cardiac Anesthesiology, MUG</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Maciej M. Kowalik</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>fenoldopam</keyword>
  <keyword>ketanserin</keyword>
  <keyword>renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenoldopam</mesh_term>
    <mesh_term>Ketanserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Upon reasonable request IPD can be made available to other researcher.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

